Sustained Remission with the Combination Biologic Doublet of Lenalidomide Plus Rituximab As Initial Treatment for Mantle Cell Lymphoma: A Multi-Center Phase II Study Report
Jia Ruan(Cornell University), John P. Leonard(New York University), Richard R. Furman(Cornell University), Paul J. Christos(Cornell University), Bijal Shah(Boston College), Orel Katz(NewYork–Presbyterian Hospital), Peter Martin(Northwestern University), Louisa Drake(Cornell University), Stephen J. Schuster(Hospital of the University of Pennsylvania), Morton Coleman(Cornell University), Jakub Svoboda(UPMC Hillman Cancer Center), Jessica Lewis(Nanotherapeutics (United States)), Sonali M. Smith(University of Chicago)
Cited by 18
Related Papers
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k